IL13 and Alzheimer disease: In the AD model of mice with IL-13 gene defects, the activation of Th2 cells is enhanced, and the relative levels of short-chain sphingomyelin (SM) and ceramide (CER), which are composed of non-hydroxy fatty acids and sphingolipids, increase, while the relative levels of long-chain types decrease (44).